Phase I results with ModraDoc006/r published in the European Journal of Cancer
October 15, 2017
14 october 2017
Researchers from the Netherlands Cancer Institute have published results from a Phase I study with oral docetaxel in the European Journal of Cancer, in a paper titled, ‘A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir’.
Read the publication in the European Journal of Cancer
This is the first publication of safety, tolerability and initial clinical activity data for ModraDoc006/r in patients with metastatic solid tumors.
